In the News

Read the FULL article here.

Rep. Neal Dunn (R-Fla.) on Tuesday said the controversial federal approval of the Alzheimer’s medication Aduhelm “muddied the waters” for other potential treatments for the disease.

Dunn on Tuesday appeared at “Accelerated Approvals & the Pathway to Treatments,” a virtual event hosted by The Hill aimed at discussing the future of treatment for Alzheimer’s disease. The event was sponsored by the nonprofit Alzheimer’s Association.

While speaking with The Hill Editor in Chief Bob Cusack, Dunn said that there were currently 20 to 30 “promising” Alzheimer’s drugs in different stages of trials.

“There’s a lot of promise out there. So I think something’s going to come across the finish line soon. The first one to make it across is of course aducanumab, or it’s sold under the name Aduhelm. So that was the first one, and it muddied the waters because it had a very abnormal approval process” said Dunn, who himself is a physician.

In June, the Food and Drug Administration (FDA) granted “accelerated approval” to Biogen’s drug despite conflicting evidence over whether it was truly effective at slowing the progression of Alzheimer’s.